209 related articles for article (PubMed ID: 35252869)
1. Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells.
Florian AC; Woodley CM; Wang J; Grieb BC; Slota MJ; Guerrazzi K; Hsu CY; Matlock BK; Flaherty DK; Lorey SL; Fesik SW; Howard GC; Liu Q; Weissmiller AM; Tansey WP
NAR Cancer; 2022 Mar; 4(1):zcac007. PubMed ID: 35252869
[TBL] [Abstract][Full Text] [Related]
2. Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity.
Aho ER; Wang J; Gogliotti RD; Howard GC; Phan J; Acharya P; Macdonald JD; Cheng K; Lorey SL; Lu B; Wenzel S; Foshage AM; Alvarado J; Wang F; Shaw JG; Zhao B; Weissmiller AM; Thomas LR; Vakoc CR; Hall MD; Hiebert SW; Liu Q; Stauffer SR; Fesik SW; Tansey WP
Cell Rep; 2019 Mar; 26(11):2916-2928.e13. PubMed ID: 30865883
[TBL] [Abstract][Full Text] [Related]
3. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
Howard GC; Wang J; Rose KL; Jones C; Patel P; Tsui T; Florian AC; Vlach L; Lorey SL; Grieb BC; Smith BN; Slota MJ; Reynolds EM; Goswami S; Savona MR; Mason FM; Lee T; Fesik S; Liu Q; Tansey WP
Elife; 2024 Apr; 12():. PubMed ID: 38682900
[TBL] [Abstract][Full Text] [Related]
4. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
Howard GC; Wang J; Rose KL; Jones C; Patel P; Tsui T; Florian AC; Vlach L; Lorey SL; Grieb BC; Smith BN; Slota MJ; Reynolds EM; Goswami S; Savona MR; Mason FM; Lee T; Fesik SW; Liu Q; Tansey WP
bioRxiv; 2024 Jan; ():. PubMed ID: 37546802
[TBL] [Abstract][Full Text] [Related]
5. Targeting WDR5: A WINning Anti-Cancer Strategy?
Aho ER; Weissmiller AM; Fesik SW; Tansey WP
Epigenet Insights; 2019; 12():2516865719865282. PubMed ID: 31360909
[TBL] [Abstract][Full Text] [Related]
6. WDR5 is a conserved regulator of protein synthesis gene expression.
Bryan AF; Wang J; Howard GC; Guarnaccia AD; Woodley CM; Aho ER; Rellinger EJ; Matlock BK; Flaherty DK; Lorey SL; Chung DH; Fesik SW; Liu Q; Weissmiller AM; Tansey WP
Nucleic Acids Res; 2020 Apr; 48(6):2924-2941. PubMed ID: 31996893
[TBL] [Abstract][Full Text] [Related]
7. WIN site inhibition disrupts a subset of WDR5 function.
Siladi AJ; Wang J; Florian AC; Thomas LR; Creighton JH; Matlock BK; Flaherty DK; Lorey SL; Howard GC; Fesik SW; Weissmiller AM; Liu Q; Tansey WP
Sci Rep; 2022 Feb; 12(1):1848. PubMed ID: 35115608
[TBL] [Abstract][Full Text] [Related]
8. Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models.
Teuscher KB; Chowdhury S; Meyers KM; Tian J; Sai J; Van Meveren M; South TM; Sensintaffar JL; Rietz TA; Goswami S; Wang J; Grieb BC; Lorey SL; Howard GC; Liu Q; Moore WJ; Stott GM; Tansey WP; Lee T; Fesik SW
Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2211297120. PubMed ID: 36574664
[TBL] [Abstract][Full Text] [Related]
9. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
Darr J; Klochendler A; Isaac S; Eden A
Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
[TBL] [Abstract][Full Text] [Related]
10. Impact of WIN site inhibitor on the WDR5 interactome.
Guarnaccia AD; Rose KL; Wang J; Zhao B; Popay TM; Wang CE; Guerrazzi K; Hill S; Woodley CM; Hansen TJ; Lorey SL; Shaw JG; Payne WG; Weissmiller AM; Olejniczak ET; Fesik SW; Liu Q; Tansey WP
Cell Rep; 2021 Jan; 34(3):108636. PubMed ID: 33472061
[TBL] [Abstract][Full Text] [Related]
11. Fragment screening for a protein-protein interaction inhibitor to WDR5.
Dennis ML; Morrow BJ; Dolezal O; Cuzzupe AN; Stupple AE; Newman J; Bentley J; Hattarki M; Nuttall SD; Foitzik RC; Street IP; Stupple PA; Monahan BJ; Peat TS
Struct Dyn; 2019 Nov; 6(6):064701. PubMed ID: 31768400
[TBL] [Abstract][Full Text] [Related]
12. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.
Darr J; Klochendler A; Isaac S; Geiger T; Eden A
Mol Cancer; 2015 Sep; 14():167. PubMed ID: 26370283
[TBL] [Abstract][Full Text] [Related]
13. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors.
McKenna ES; Tamayo P; Cho YJ; Tillman EJ; Mora-Blanco EL; Sansam CG; Koellhoffer EC; Pomeroy SL; Roberts CW
Cell Cycle; 2012 May; 11(10):1956-65. PubMed ID: 22544318
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.
Kim KH; Roberts CW
Cancer Genet; 2014 Sep; 207(9):365-72. PubMed ID: 24853101
[TBL] [Abstract][Full Text] [Related]
16. SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.
Wei D; Goldfarb D; Song S; Cannon C; Yan F; Sakellariou-Thompson D; Emanuele M; Major MB; Weissman BE; Kuwahara Y
Mol Cancer Res; 2014 Nov; 12(11):1574-85. PubMed ID: 25009291
[TBL] [Abstract][Full Text] [Related]
17. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
Kuwahara Y; Wei D; Durand J; Weissman BE
Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
[TBL] [Abstract][Full Text] [Related]
18. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
[TBL] [Abstract][Full Text] [Related]
19. p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition.
Oppel F; Shao S; Gendreizig S; Zimmerman MW; Schürmann M; Flavian VF; Goon P; Chi SN; Aster JC; Sudhoff H; Look AT
Mol Cancer Ther; 2022 Nov; 21(11):1689-1700. PubMed ID: 36099437
[TBL] [Abstract][Full Text] [Related]
20. Generation of a mouse model of atypical teratoid/rhabdoid tumor of the central nervous system through combined deletion of Snf5 and p53.
Ng JM; Martinez D; Marsh ED; Zhang Z; Rappaport E; Santi M; Curran T
Cancer Res; 2015 Nov; 75(21):4629-39. PubMed ID: 26363008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
